Burlington, Mass. ‒ April 18, 2012 – inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has launched EMBARX™, a customizable, patient-centric offering to meet the market access challenges of specialty biotech and pharmaceutical products. EMBARX draws upon leading industry experts from inVentiv’s Clinical, Commercial and Consulting segments and uses state-of-the-art technology to create comprehensive solutions that improve patient access, increase commercial value, and drive adherence and loyalty to clients’ products.
EMBARX includes services such as strategic consulting, reimbursement support, clinical nursing teams, adherence programs, REMS, payer communications, and field teams support. EMBARX leaders bring a thorough understanding of specialty diseases, product cycles, care settings, product markets and drug class characteristics. Each EMBARX solution is completely customized with the patient, provider, and payer in mind. Because the services are delivered through inVentiv Health, clients experience the convenience and efficiency of working with one provider to manage fully integrated, multi-service programs.
“While a growing number of innovative specialty products are being introduced to the market, it is also becoming increasingly difficult for patients to access those therapies due to regulatory, cost and educational barriers,” said Mark Dmytruk, President of inVentiv Health Patient Outcomes. “EMBARX leverages inVentiv’s talent and experience to provide powerful solutions to these market access challenges. Through our integrated teams, we not only support the business goals of our clients, we also help drive improved patient outcomes.”
To learn more about EMBARX, please contact Anthony Piagentini, Executive Director, Business Development, at firstname.lastname@example.org or 732-584-5288. Additional information is also available at http://www.inventivhealth.com/embarx.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv’s client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.